Proposal for agar disk diffusion interpretive criteria for susceptibility testing of bovine mastitis pathogens using cefoperazone 30 μg disks

Veterinary Microbiology

Volumn 200, Issue , 2017, Pages 65-70

  Feßler, Andrea T ^a   Kaspar, Heike ^b   Lindeman, Cynthia J ^c   Peters, Thomas ^d   Watts, Jeffrey L ^c   Schwarz, Stefan ^a  

^a FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^b Federal Office of Consumer Protection and Food Safety (BVL)   (Germany)

^c ZOETIS   (United States)

^d Milchtierherden Betreuungs und Forschungsgesellschaft mbH (MBFG)   (Germany)

Author keywords

3rd generation cephalosporins; Dairy cattle; Zone diameters

Indexed keywords

CEFOPERAZONE; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BOVINE MASTITIS; CLINICAL OUTCOME; CONTROLLED STUDY; DISK DIFFUSION; INFECTION SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS DYSGALACTIAE; STREPTOCOCCUS UBERIS; ANIMAL; BOVINE; CHEMISTRY; DRUG EFFECTS; ESCHERICHIA COLI; FEMALE; MICROBIOLOGY; MILK; STANDARDS; STREPTOCOCCUS; VETERINARY;

ANIMALS; ANTI-BACTERIAL AGENTS; CATTLE; CEFOPERAZONE; DISK DIFFUSION ANTIMICROBIAL TESTS; ESCHERICHIA COLI; FEMALE; MASTITIS, BOVINE; MILK; STREPTOCOCCUS;

EID: 84960511196     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2016.02.026     Document Type: Article

References (18)

1. Bradford, P.A., Sanders, C.C., Use of a predictor panel for development of a new disk for diffusion test with cefoperazone-sulbactam. Antimicrob. Agents Chemother. 36 (1992), 394–400.
2. Brunden, M.N., Zurenko, G.E., Kapik, B., Modification of the error-rate bounded classification scheme for use with two MIC break points. Diagn. Microbiol. Infect. Dis. 15 (1992), 135–140.
3. Clinical and Laboratory Standards Institute (CLSI), Development of in vitro susceptibility testing criteria and quality control parameters for veterinary antimicrobial agents; approved guideline. CLSI Document VET02-A3 (formerly M37-A3), third edition, 2008, Clinical and Laboratory Standards Institute, Wayne, PA, USA.
4. Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard. CLSI Document VET01-A4, fourth edition, 2013, Clinical and Laboratory Standards Institute, Wayne, PA, USA.
5. Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. CLSI Document M100-S25, 2015, Clinical and Laboratory Standards Institute, Wayne, PA, USA.
6. Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; third informational supplement. CLSI Document VET01-S, third edition, 2015, Clinical and Laboratory Standards Institute, Wayne, PA, USA.
7. European Agency for the Evaluation of Medical Products (EMEA), 1998. Committee for veterinary medical products, Cefoperazone. Summary report (1). EMEA/MRL/512/98-FINAL available at: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500011856.pdf.
8. Feßler, A.T., Billerbeck, C., Kadlec, K., Schwarz, S., Identification and characterization of methicillin-resistant coagulase-negative staphylococci from bovine mastitis. J. Antimicrob. Chemother. 65 (2010), 1576–1582.
9. Feßler, A.T., Kaspar, H., Lindeman, C.J., Stegemann, M.R., Peters, T., Mankertz, J., Watts, J.L., Schwarz, S., A proposal of interpretive criteria for cefoperazone applicable to bovine mastitis pathogens. Vet. Microbiol. 157 (2012), 226–231.
10. ® 25922. Vet. Microbiol. 171 (2014), 284–289.
11. Haenni, M., Saras, E., Madec, J.-Y., Demonstration of a shift towards penicillin resistance in the Streptococcus uberis population. J. Med. Microbiol. 59 (2010), 993–995.
12. Haenni, M., Galofaro, L., Ythier, M., Giddey, M., Majcherczyk, P., Moreillion, P., Madec, J.-Y., Penicillin-binding protein gene alterations in Streptococcus uberis isolates presenting decreased susceptibility to penicillin. Antimicrob. Agents Chemother. 54 (2010), 1140–1145.
13. Hamann, J., Hahne, K.-H., Heeschen, W., 1986. Expert report on the elimination behaviour of the preparation, Cefoperazone Mastitis after intracisternal (intramammary) application to lactating cows in different doses.
14. Jorgensen, J.H., Turnidge, J.D., Washington, J.A., Antibacterial susceptibility tests: dilution and disk diffusion methods. Manual of Clinical Microbiology, 7th edition, 1999, ASM Press, Washington, D.C, 1526–1543.
15. Lindeman, C.J., Portis, E., Johansen, L., Mullins, L.M., Stoltman, G.A., Susceptibility to antimicrobial agents among bovine mastitis pathogens isolated from North American dairy cattle, 2002–2010. J. Vet. Diagn. Invest. 25 (2013), 581–591.
16. Schwarz, S., Silley, P., Simjee, S., Woodford, N., van Duijkeren, E., Johnson, A.P., Gaastra, W., Assessing the antimicrobial susceptibility of bacteria obtained from animals. Vet. Microbiol. 141 (2010), 1–4.
17. Weiskopf, S., 1987. Efficacy of cefoperazone 100 in bovine clinical mastitis. Pfizer Document 2132Q-10–86-132/100, pp. 221–250.
18. Wilson, C.D., Gilbert, G.A., Pharmacokinetics of cefoperazone in the cow by the intramammary route and its effect on mastitis pathogens in-vitro. Vet. Rec 118 (1986), 607–609.